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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive, chronic respiratory disease with a significant
socioeconomic burden. Exacerbations, the sudden and sustained worsening of symptoms, can lead to hospitalization and reduce
quality of life. Major limitations of previous telemonitoring interventions for COPD include low compliance, lack of consensus
on what constitutes an exacerbation, limited numbers of patients, and short monitoring periods. We developed a telemonitoring
system based on a digital health platform that was used to collect data from the 1-year EDGE (Self Management and Support
Programme) COPD clinical trial aiming at daily monitoring in a heterogeneous group of patients with moderate to severe COPD.
Objective: The objectives of the study were as follows: first, to develop a systematic and reproducible approach to exacerbation
identification and to track the progression of patient condition during remote monitoring; and second, to develop a robust algorithm
able to predict COPD exacerbation, based on vital signs acquired from a pulse oximeter.
Methods: We used data from 110 patients, with a combined monitoring period of more than 35,000 days. We propose a finite-state
machine–based approach for modeling COPD exacerbation to gain a deeper insight into COPD patient condition during home
monitoring to take account of the time course of symptoms. A robust algorithm based on short-period trend analysis and logistic
regression using vital signs derived from a pulse oximeter is also developed to predict exacerbations.
Results: On the basis of 27,260 sessions recorded during the clinical trial (average usage of 5.3 times per week for 12 months),
there were 361 exacerbation events. There was considerable variation in the length of exacerbation events, with a mean length
of 8.8 days. The mean value of oxygen saturation was lower, and both the pulse rate and respiratory rate were higher before an
impending exacerbation episode, compared with stable periods. On the basis of the classifier developed in this work, prediction
of COPD exacerbation episodes with 60%-80% sensitivity will result in 68%-36% specificity.
Conclusions: All 3 vital signs acquired from a pulse oximeter (pulse rate, oxygen saturation, and respiratory rate) are predictive
of COPD exacerbation events, with oxygen saturation being the most predictive, followed by respiratory rate and pulse rate.
Combination of these vital signs with a robust algorithm based on machine learning leads to further improvement in positive
predictive accuracy.
Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 40367841;
http://www.isrctn.com/ISRCTN40367841 (Archived by WebCite at http://www.webcitation.org/6olpMWNpc)
(J Med Internet Res 2017;19(3):e69)   doi:10.2196/jmir.7207
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Introduction
Chronic obstructive pulmonary disease (COPD) is expected to
become the fourth leading cause of death by 2030 [1], imposing
a high socioeconomic burden worldwide [2]. It is a chronic,
progressive condition caused by airway infection due to smoking
or long-term exposure to pollutants (eg, dust, fumes, poor air
quality) irritating lungs. Common symptoms of COPD include
coughing, chest tightness, breathlessness, fatigue, dizziness,
and wheezing. Patients with COPD suffer from “exacerbations,”
a sustained worsening of symptoms often leading to
hospitalization. In the United Kingdom, COPD exacerbations
are now the leading cause of hospitalization, accounting for
15.9% of all hospital admissions [3]. There is growing evidence
to suggest that increased frequency of exacerbation episodes
leads to faster decline in lung function, reduced quality of life,
greater numbers of hospital admissions, and increased health
care cost [4]. Exacerbation is thus widely used as a major
outcome in clinical studies for patients with COPD, with
increasing efforts to try and reduce them. These efforts are
hampered by the wide variation in the definitions of exacerbation
used in clinical studies, with some based on symptoms (eg,
increased breathlessness, sputum volume/color), some on events
(eg, requiring hospitalization, taking antibiotics, and/or steroids),
and some using a combination of both symptoms and events
[4]. Symptoms are typically reported by the patients themselves
using a paper-based diary and hence their recording depends
on a subjective assessment. Poor adherence to protocol and data
validity issues in clinical studies are often cited as major
disadvantages of this approach [4]. Event-based definitions, on
the other hand, are based on assessment by health care
professionals (HCPs) after contact with them has been made by
the patient. The disadvantage here is the low level of reporting
to HCPs, with as many as 50% of exacerbations being
unreported [5]. Until recently, exacerbations could only be
identified from patient interviews or from analysis of records
of treatment in health care databases or of symptom diary cards
filled manually by patients [6].
Telemonitoring allows patients to record their symptoms in real
time. Symptom data can then be stored and transmitted, with
instant access possible for HCPs. As a result, there have been
a number of attempts to use telemonitoring solutions to help
manage patients with COPD through early detection of
deterioration [7]. However, low compliance, lack of consensus
on what constitutes an exacerbation, the small number of patients
in most studies, and the relatively short periods of time during
which monitoring takes place (less than 6 months) are limitations
of COPD telemonitoring interventions [7]. In order to address
these challenges, we developed the EDGE (Self Management
and Support Programme) digital health system, a telemonitoring
platform first evaluated during a cohort study [8] and
subsequently used for 12 months, in a randomized controlled
trial (RCT), by 110 patients in the intervention group [9]. The
EDGE digital system allows patients to report their symptoms
directly on an Internet-enabled tablet computer with a
user-friendly interface, thereby eliminating most data validity
issues. In the RCT, patients were expected to manage their use
of relievers, antibiotics, and steroids and record it as part of the
symptom diary on the tablet computer. Medication usage data
linked to the symptom data were thus available, and so events
could be defined based on medication data without the
requirement of contact with an HCP. The system was intuitive
and easy to use leading to high patient compliance and the
collection of large amounts of COPD patient data [9].
Exacerbations are characterized by a number of different
scenarios: for example, a patient’s medication changes but the
symptoms do not change; a patient's symptoms change, but the
intake of medication does not change; or the patient’s symptoms
get worse without the patient taking any medication and there
is no change for a few days before the patient eventually takes
his or her medication. A systematic approach to address such a
complex problem is to model it using a finite-state machine
(FSM). Assuming that exacerbations can be correctly identified
using such an approach, the next step is to investigate if a robust
algorithm can be developed to predict exacerbation episodes.
This is especially challenging because the protocol for the RCT
allowed patients to self-monitor and record their symptom and
medication data at a time of their choosing. There were periods,
for some patients, during which they self-monitored less
frequently and other periods with more frequent data but for
different times of the day. Any predictive algorithm must be
robust to such irregular sampling and take the variable timing
of data recording into account.
In previous work, we developed an algorithm using the EDGE
cohort study data, with a limited definition of
exacerbation—based on self-reported medication usage,
self-reported symptoms, and pulse oximetry data [10,11]. We
did not differentiate between correlation and prediction, as the
entire period, both before and during an exacerbation, was
considered. Ideally, any predictive algorithm developed should
identify periods likely to be associated with an impending
exacerbation and differentiate them from periods where a
patient’s condition is stable (including periods of sustained high
medication usage).
Methods
Overview
This section first describes the EDGE digital health system used
to collect data from the 110 patients in the intervention group
during the RCT. Next, the FSM model for identifying
exacerbation episodes from symptom and medication usage
data is introduced. This is followed by a description of the
procedure for extracting “stable” and “prodromal” periods to
provide the training data for an exacerbation prediction
algorithm relying on robust features. Finally, the classification
and validation methodologies adopted are presented.
Self Management and Support Programme System
The EDGE system is a digital health system with an
Internet-enabled tablet computer at its core to support
self-monitoring and self-management. The main components
include a customized application developed for patients with
COPD in collaboration with clinicians and patients, a
Bluetooth-enabled pulse oximeter, and a secure back-end server.
The application includes several self-monitoring modules,
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including an interactive symptom diary with a series of questions
related to COPD symptoms and to medication usage. A
“session” consists of completing a symptom diary questionnaire
and a brief recording with a pulse oximeter using a finger probe
and typically lasts about 100 seconds [8]. The interactive diary
questionnaire allows patients to self-report whether their
symptoms have improved, become worse, or not changed
compared with their understanding of what is “usual” for them.
Chest tightness, breathlessness, sputum volume, and purulence
are treated as “major” symptoms, while having a cold or sore
throat, and an assessment of feeling generally run down, are
treated as “minor” symptoms. Patients also report whether they
are taking relievers, antibiotics, or steroids or any combination
of the 3.
Finite-State Machine Model for COPD Exacerbation
According to the World Health Organization (WHO) and US
National Heart, Lung, and Blood Institute Global Initiative for
Chronic Obstructive Lung Disease (GOLD), an exacerbation
is defined as “an event in the natural course of the disease
characterized by a change in the patient’s baseline dyspnea,
cough, or sputum that is beyond normal day-to-day variations,
is acute in onset, and may warrant a change in regular
medication in a patient with underlying COPD.” Although the
definition is comprehensive, it raises a number of questions (eg,
what are “normal day-to-day variations”?), thereby limiting its
adoption as a practical definition in the context of clinical
studies.
An FSM is a mathematical abstraction extensively used in the
domain of logic design [12]. In FSM models, there are a finite
number of “states” and a machine can transition from one state
to another depending on “inputs.” In this context, the “machine”
will model a patient, and “inputs” are changes in symptoms
and/or medication uptake. A patient will be in a particular “state”
at any given time. Depending on changes in symptoms or
medication usage, the patient’s state can transition to another
state. In addition to a “normal” state and an “exacerbation” state,
we define a “transitional” state to account for those situations
in which the patients are not in their normal state but their
condition is not poor enough for them to be considered as having
an exacerbation.
As already mentioned, there are a large number of exacerbation
definitions. The following definition of exacerbation, based on
clinical experience and a comprehensive review of the literature,
was adopted by the clinical experts running the EDGE RCT:
“An exacerbation is defined as a change in medication or an
HCP contact (hospital admission or any documented contact,
face-to-face contact or telephone calls) in the presence of a
significant increase in symptoms.”
“Change in medication” or “medication event” is defined as (1)
increased use of reliever inhaler for at least 48 hours and (2)
starting oral steroids and/or antibiotics. “Significant increase in
symptoms” is defined as the presence of at least two symptoms,
one of which should be a major symptom.
The 3 states in the FSM-based model are “normal” (patient is
completely normal), “transitional” (patient’s symptoms have
become worse but no medication event or hospital admission
or contact with HCP), and “exacerbation.” Completion of a new
symptom diary questionnaire generates a new set of inputs.
Figure 1 shows the FSM model with its 3 states and the
transitions between them depending on the 3-bit “inputs”
encoding different combinations of symptoms and medication
usage. The first bit encodes medication usage (0 = no medication
or usual medication; 1 = medication event, as defined above).
The second and third bits encode the status of the self-reported
symptoms (00 = no change in symptoms; 10 = symptoms get
worse; 11 = symptoms improve). It can be seen from Figure 1
that patients stay in the normal state regardless of whether they
take medication or not, unless their symptoms get worse. Once
a patient’s symptoms get worse, he or she either transitions to
a transitional state or into the exacerbation state, depending on
whether there is a change in medication or medication event,
as defined above. In the transitional state, a patient returns to
the normal state if his or her symptoms improve (regardless of
whether a medication event occurs or does not occur). Whenever
the symptoms have not improved, a transition to the exacerbation
state occurs instead if there is a medication event, or if the
patient is hospitalized or makes contact with an HCP (regarding
his or her COPD symptoms). In the exacerbation state, a patient
only transitions back to the normal state if his or her symptoms
improve. The definition of symptom improvement is a mirror
image of the definition of “symptoms getting worse” given
above: at least two symptoms, one of which must be a major
symptom, must get better in comparison with the data recorded
in the previous diary session.
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Figure 1. A finite-state machine to model chronic obstructive pulmonary disease patient condition and its changes depending on symptoms and
medication usage. HCP: health care professional.
Selection of Independent Periods
In order to develop algorithms for prediction of exacerbation
episodes, it is important first to identify the periods of time (in
days) during which a patient’s condition is stable, as well as
periods of time when a patient’s condition can be considered
to be deteriorating before an exacerbation event. A previous
study [13] has suggested that symptoms tend to worsen during
the 7 days immediately before an exacerbation episode. We
therefore define a time window of 7 days before an exacerbation
event and label all such instances in our dataset as “prodromal”
periods. Similarly, “stable” periods are defined as 7-day periods
during which a patient must be in the normal state throughout.
These periods have a 7-day “guard band” at the start and the
end of the period. This is to ensure that, for every stable period,
there are at least 7 days at the start of the stable period since a
transitional or exacerbation state ended and at least 7 days at
the end of the stable period before the next transitional or
exacerbation state occurs.
Figure 2 illustrates the identification of “stable” and “prodromal”
periods for a single subject who was in different states over the
course of the trial.
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Figure 2. Identification of “stable periods” and “prodromal periods” over the course of monitoring of a single patient. Notice that there are only 4 stable
periods identified between the time when the patient returns to normal from the transitional state and the time when the patient goes from normal to the
transitional state. There is only 1 stable period after the patient returns to normal after the first exacerbation and before the second exacerbation occurs.
In this illustration, each vertical line represents a single day, and “stable,” “prodromal,” and “guard bands” are all 7 days long.
Vital Signs From Pulse Oximetry
Commercial pulse oximeters typically provide only oxygen
saturation (SpO2) and pulse rate measures. However, it is also
possible to extract respiratory rate using the waveform—called
photoplethysmogram (PPG)—recorded by a pulse oximeter
with an appropriate algorithm. Briefly, respiratory rate
modulates both the amplitude (primarily due to the mechanical
effect of breathing) and frequency (due to respiratory sinus
arrhythmia) of the PPG [14]. In the analysis presented in this
paper, we focus on extracting respiratory rate from the amplitude
modulation of the PPG because the phenomenon of respiratory
sinus arrhythmia is reduced both with age [15] and
pharmacological interventions [16]. The method used for
estimating respiratory rate from the PPG waveform was based
on computing the median frequency spectrum from a number
of autoregressive models of the 30-second waveform segments
recorded during the self-monitoring with the finger probe pulse
oximeter. This novel signal processing approach was developed
by us to estimate respiratory rate from PPG data in a different
clinical setting [17]. Estimation of the respiratory rate from the
amplitude modulation of the PPG requires a preprocessing stage
in which an appropriate low-pass filter attenuates as much
high-frequency content (corresponding to the cardiac frequency)
as possible while preserving the low-frequency content
(corresponding to the respiratory frequency). Because the work
described in [17] was based on a population of pediatric patients
with different values of respiratory and heart rates, the
preprocessing stage was modified to take into account the lower
values of respiratory and heart rates in the adult population. The
cutoff frequencies of the transition band of the low-pass filter
were varied according to the heart rate of the patient in a given
session (ie, from 0.5 × heart rate to 1.2 × heart rate).
Consequently, for each recording session from a participant in
the RCT, 3 vital signs (heart rate, SpO2, and respiratory rate)
were obtained from the 30-second pulse oximetry data.
Feature Extraction
The labeling shown in Figure 2 is used to create a database of
vital sign data from 7-day stable periods and 7-day prodromal
periods (ahead of the exacerbation events). This database will
enable us to construct a 2-class classifier, with the vital sign
data as its inputs, to assign the data to either the stable or
prodromal class. Classification of a 7-day period as prodromal
is of course equivalent to exacerbation prediction.
It is important to capture the time course of each vital sign
during these 7-day periods. A number of traditional algorithms
developed for time series analysis cannot be directly applied
because of the irregular number of recordings over a given
period, both within and across subjects. Rather than applying
approximations, for example, grouping multiple recording
sessions within a day together (a rare occurrence), or imputing
missing data (a much more common phenomenon), we fit a
straight line, using a least squares criterion, to each set of vital
sign data in each period. This corresponds to finding the
minimum of E (m,c) defined in equation (a) in Figure 3, where
m is the gradient, xi is the time at which the i
th session was
recorded in a given 7-day period, yi is the corresponding value
of the vital sign, and c is the y-intercept value. For each vital
sign in each 7-day period, the minimization of equation (a) will
provide the gradient, m, whose magnitude will reflect whether
the value of the vital sign is increasing, decreasing, or not
changing, and an intercept value that is dependent on both the
mean value and the gradient.
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Each 7-day period is normalized in time with respect to the first
self-monitoring session in that period (the first session in each
7-day period is taken to be at time 0). Figure 4 illustrates this
for 2 cases, a “stable” period and a “prodromal” period. In this
particular illustration, it can be seen that the patient in the stable
period had a higher mean respiratory rate, which was gradually
decreasing during the 7 days. The patient in the prodromal
period has a lower mean respiratory rate but there is a clear
increase over the 7 days. With this simple linear fit method, we
capture the trend of each vital sign over the 7 days. Periods with
irregular self-monitoring times or missing data can still be
analyzed.
Figure 3. (a) Least Squares Fitting to determine the gradient and y-intercept
in each 7-day period(b) Hypothesis function (c) Sigmoid function(d) Cost
function for logistic regression.
Figure 4. Illustration of straight line fitting during a “stable” period (gradient: −0.60, y-intercept: 17.5) and a “prodromal” period (gradient: 1.43,
y-intercept: 18.47).
Classification and Validation
A logistic classifier was applied to the vital sign feature vectors
derived from both the stable and prodromal periods in order to
investigate the discriminatory power of these features for
classification (and hence exacerbation prediction). Equation (b)
in Figure 3 gives the hypothesis function used in logistic
regression where xn and θn are the n
th feature and parameter,
respectively, and s (y) is a sigmoid function (equation (c) in
Figure 3). The output of the sigmoid function is bounded
between 0 and 1 and can thus be interpreted as a probability or,
in this case, the likelihood of a patient’s condition deteriorating
and leading to exacerbation (the prodromal period). The mean
and gradient values (xn) of each of the 3 vital signs are the inputs
to the logistic classifier.
The cost function given by equation (d) in Figure 3 outputs a
large value when the predicted value hθ(x), is very different
from the true class value, y, and a very small output when the
predicted value is close to the true class value. An additional
benefit of C (θ) as a cost function is that it is convex and thus
a global minimum will always exist, which can easily be
determined with a gradient descent algorithm.
Correct classification of a prodromal period was deemed to be
a true positive and correct classification of a stable period was
deemed to be a true negative. Incorrect classifications of
prodromal periods and stable periods were taken to be false
negatives and false positives, respectively. To test the
generalization capability of the classification algorithm, we used
10-fold cross-validation. The data from both classes were
randomly divided into 10 folds, with 9 folds used for training
and 1 fold for testing. This was repeated 10 times, each time
using a different fold for testing. This allowed us to obtain
classification results on the whole dataset. Because the
partitioning of data into 10 folds is random, the process of
applying 10-fold cross-validation was repeated 1000 times,
thereby allowing us to find the possible range of classifier
performance. For performance evaluation, the receiver operating
characteristic (ROC) curve was determined for each iteration
and the mean ROC curve along with the 95% confidence interval
was then computed. We then estimated the area under the curve
(AUC) to compare the different classifiers.
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Results
Dataset
Table 1 provides summary statistics on the number of days,
sessions, and compliance of the 100 patients in the RCT
intervention group with near-complete symptom diary and pulse
oximetry data. On average, a patient self-monitored for 354
days, with a minimum usage of 5 days every week throughout
this period.
Table 1. Overall number of days, sessions, and compliance of 100 patients in the EDGE (Self Management and Support Programme) study with both
symptom diary and pulse oximetry data.
Per patientAcross all patientsMetric
RangeMean (SD)
194-403354 (31)35,439Number of days in study
61-373273 (68)27,260Number of sessions
60-373271 (67)27,074Number of days system used
1.8-6.95.3 (1.2)Mean compliance (days/week)
Identification of Exacerbations
There were a total of 361 exacerbation events after applying the
proposed FSM model to the 27260 sessions from 100 patients.
Figure 5 summarizes the total number of sessions in each state
(given inside the circles), as well as the number of times that a
patient transitioned from one state to the other (given next to
the corresponding arrow). As expected, patients were mostly
in the normal state (18,920/27,260, 69.41% of sessions
completed) and were in the transitional state for 22.40%
(6105/27,260) of the sessions. In 2174 instances, patients in the
normal state entered the transitional state as a result of their
symptoms deteriorating but without increasing their medication.
In 93.24% of these cases (2027/2174), their symptoms
subsequently improved and they returned to the normal state.
For 97.08% of the 2027 cases (1968/2027), this happened
without any medication increase; in only 2.91% of the cases
(59/2027) did patients increase their medication before returning
to the normal state. In the cases for which patients did not
increase their medication while returning to normal state, the
mean and median number of days in the transitional state were
3.2 days and 1.8 days. In the cases for which patients increased
their medication while returning to normal state, the mean and
median number of days in the transitional state were 4.2 days
and 3.0 days.
Only 2235 sessions (8.20% of total sessions, 2235/27,260) were
completed while the patient was in the exacerbation state. In
64.0% of cases (231/361), a patient’s state transitioned directly
from the normal to the exacerbation state, corresponding to
patients increasing their medication as soon as their self-reported
symptoms got worse.
All patients were assumed to be in the normal state at the start
of the RCT, but only 71 patients ended up being in the normal
state at the end of the study, with the remaining 29 patients
ending in either the transitional state or the exacerbation state.
Thus, there were 29 more transitions out of the normal state
(2405) than into the normal state (2376) and also 17 and 12
extra transitions into the transitional and exacerbation states,
respectively.
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Figure 5. Summary of state transitions illustrating the total number of sessions in each state (inside the circles) and the number of instances of each
transition between states across all patients (numbers next to the arrow between states) in the randomized controlled trial.
Distribution of Exacerbations
Table 2 and Figure 6 illustrate the distribution of length of
exacerbation episodes. It can be seen that most of the
exacerbation episodes lasted for up to 7 days (260/361, 72%).
However, there was considerable variation in the length of an
exacerbation episode across the population, with a mean length
of 8.8 days and a median length of 4 days. On the basis of the
total number of monitoring days, patients were in the
exacerbation state for about 9% of the time (3180/35,439
monitoring days).
Table 2. Length of exacerbation events across all patients (91.7% of exacerbation episodes, 331/361, were within 21 days).
NumberMetric
361Total number of events
260 (72.0)Event length 1-7 days, n (%)
50 (13.9)Event length 8-14 days, n (%)
21 (5.8)Event length 15-21 days, n (%)
8.8Mean length of exacerbation, days
4 (2-9)Median length (interquartile range) of exacerbation, days
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Figure 6. Distribution of exacerbation length (only those with episodes lasting 21 days or less are shown).
Characteristics of Vital Signs During Stable and
Prodromal Periods
Table 3 summarizes the total number of periods and the
corresponding number of sessions, as well as summary statistics
for the various features extracted for each of these periods, both
stable and prodromal periods. Even though there were 361
exacerbation events, in only 304 of those cases were there at
least 7 days immediately before the exacerbation event during
which the patient was either in the normal or the transitional
state. The remaining cases refer to exacerbation events that
occurred within 7 days of a previous exacerbation event. In 18
out of these 304 cases, there was only a single diary session
completed by the patient and therefore it was not possible to
extract features. This explains why there are 286 prodromal
periods extracted from this dataset, from a total of 361
exacerbation events.
It can be seen from Table 3 that the mean values for all 3 vital
signs are as expected for COPD patients with worsening
symptoms: lower mean for SpO2 and higher mean for both
respiratory rate and heart rate in the prodromal periods in
comparison with the stable periods. Figure 7 illustrates the
distribution of the 3 vital signs in the stable and prodromal
periods. The small difference in the means and the significant
overlap between the distribution of the 3 vital signs possibly
explain the difficulty of designing algorithms capable of
predicting exacerbation episodes.
Table 3. Summary statistics of different features in the stable and prodromal periods.
“Prodromal” period“Stable” periodMetric
2861005Total number of 7-day periods
4.65.9Mean number of sessions in these 7-day periods
9394Mean value of SpO2
a (%)
8380Mean value of pulse rate (beats per minute)
2422Mean value of respiratory rate (breaths per minute)
aSpO2: oxygen saturation.
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Figure 7. Distribution of vital signs (pulse rate, oxygen saturation or SpO2, and respiratory rate) acquired from a pulse oximeter in “stable” and
“prodromal” periods.
Prediction of Exacerbations
Finally, Figure 8 illustrates the mean ROC curve, bounded by
the 95% confidence interval, after applying the logistic classifier
to the stable and prodromal periods as explained in the
“Classification and Validation” section. Table 4 summarizes
the performance results using AUC measures from the mean
ROC curve (along with the 95% confidence interval) based on
classification with each of the features extracted from each of
the vital signs separately and in all possible combinations. In
addition, specificity at specific sensitivity measures is also
provided to give a better sense of the level of performance that
could be expected for a given operating point (threshold)
selected from the mean ROC curve. All 3 vital signs have a
degree of predictivity because the mean AUC is greater than .5
for all of them. SpO2 seems to be the most predictive vital sign,
followed by respiratory rate estimated using our algorithm. In
comparison with respiratory rate and SpO2, pulse rate seems to
be the least predictive in this population.
Table 4. Comparison of classifier performance using features extracted from each of the vital signs separately and in combination; the sensitivity and
specificity values are those extracted from mean receiver operating characteristic curve.
Specificity range (%) for 60%-80% sensitivity from
mean ROCb curve
Mean AUCa (95% CI)Vital sign
52-310.578 (0.578-0.578)Pulse rate (PR)
62-380.658 (0.657-0.658)SpO2
c
53-320.605 (0.604-0.605)Respiratory rate (RR)
63-400.664 (0.664-0.664)PR + SpO2
55-270.612 (0.612-0.612)RR + PR
64-360.672 (0.671-0.672)RR + SpO2
68-360.682 (0.681-0.682)RR + PR + SpO2
aAUC: area under the curve.
bROC: receiver operating characteristic.
cSpO2: oxygen saturation.
The amount of improvement possible as a result of combining
vital signs in the classification algorithm can be seen from the
two lower rows in Table 4. All 3 vital signs are derived from a
single device and have a degree of correlation for physiological
reasons. However, it can be seen that classifiers using respiratory
rate, pulse rate, and SpO2 as inputs give the best AUC results,
suggesting that there is more predictive information captured
when these vital signs are used together. These results suggest
that, in order to predict 8 exacerbations out of 10 (80%
sensitivity), there would be approximately 6 false alarms out of
10 (36% specificity). If instead the aim was to predict 6
exacerbations out of 10 (60% sensitivity), this would give rise
to approximately 3 false alarms in every 10 (68% specificity).
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Figure 8. Receiver operating characteristic showing the sensitivity and specificity (mean of 1000 iterations) when using the mean and gradient of pulse
rate, SpO2, and respiratory rate as input features to the classifiers. Note that the confidence interval is not shown because it is very narrow and the
corresponding curves overlap the mean line on the scale shown.
Discussion
Principal Findings
Our digital health system enabled reliable and regular
self-monitoring of both symptom and pulse oximetry data by
patients with COPD for a sustained period of 12 months. This
allowed the acquisition of a unique dataset, with more than
35,000 monitoring days (average of 5.3 times per week). We
have also presented a systematic approach to modeling COPD
exacerbations based on FSMs. This provides a deeper insight
into how a COPD patient’s condition progresses over time. For
example, this study showed that in about 97% of the cases for
which patients went from the normal state to the transitional
state and then back again to the normal state, they did so without
increasing their medication. This could be described as normal
variation (ie, normal variation in symptoms that does not warrant
a change in regular medication). We are not aware of any
previous study that has been able to quantify and report this
finding from such a large dataset.
A limitation of this study is that the results presented are based
on the application of a specific definition of exacerbation. In
addition, both the symptom diary information and the medication
data used to identify exacerbation episodes are self-reported by
the patients. Finally, any exacerbation event occurring while
the patient is in a transitional state and contacts an HCP or is
admitted to hospital is not identified in our analysis because of
lack of availability of this information.
The first step in developing a predictive algorithm is to decouple
periods for which a patient’s condition is completely stable from
those for which a patient is approaching an exacerbation event
(the prodromal period). This paper described a possible approach
to the development of a predictive algorithm robust to irregularly
sampled data as well as missing data. The features used as inputs
to the proposed algorithm were the mean and gradient of each
of the vital signs (pulse rate and SpO2) acquired by the pulse
oximeter or estimated from the pulse oximetry PPG data
(respiratory rate) for that 7-day period. A predictive algorithm
based on physiological data rather than self-reported symptoms
could be really helpful to support self-management in COPD.
Pinnock et al [18] report that analysis of previous telemonitoring
data suggests that it is the minority of patients who are able to
log discrete episodes of increased breathlessness, cough, and
sputum.
This study has demonstrated and quantified the predictive power
of 3 vital signs (pulse rate, SpO2, and respiratory rate) and also
shown that they can reliably be obtained in home-monitoring
with only a pulse oximeter. This coupled with the fact that only
a minority of patients with COPD are able to log episodes of
worsening symptoms suggests that the use of a pulse oximeter
should be considered in any future study involving remote
monitoring of patients with COPD. In addition to extracting
respiratory rate, we also explored the possibility of gaining more
information from the pulse oximeter waveform (the PPG). A
patient in the prodromal period is likely to have a more irregular
respiratory pattern, with a greater proportion of power in
higher-frequency bands as his or her condition worsens.
However, no features associated with the spectral content of
the respiratory signal extracted from the PPG provided any
further information once the respiratory rate was extracted. We
also explored the use of the standard deviation and y-intercept
of each of the vital signs in the 7-day periods as additional
features, but again this did not lead to improvement in the
performance of the predictive algorithm. We also investigated
if the classification performance could be improved using
support vector machines, decision trees, or k-nearest
neighbor–based classifiers [19]. However, none of these
algorithms led to any significant improvement with respect to
logistic regression. This suggests that further improvements are
more likely to come from the use of independent features not
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explored in this study (eg, temperature, activity monitoring [20],
heart rate variability [21], or automated sputum analysis [22]).
We are not aware of any previous work that has proposed FSM
or similar models in order to identify COPD exacerbations and
track the condition of patients with COPD during remote
monitoring. Furthermore, we are not aware of any previous
study that has reported respiratory rate measurements from
patients with COPD during home monitoring (except one study
[23], which only looked at patients requiring domiciliary oxygen,
a very specific and narrow segment of the population of patients
with COPD, for only 3 months). In this paper, we have reported
the distribution of 3 vital signs (pulse rate, SpO2, and respiratory
rate) during both stable and prodromal periods based on
measurements from 100 patients with COPD, providing very
frequent measurements over a 12-month period. The majority
of previous studies using telemonitoring for COPD were shorter
than 12 months [7]. Of the few studies [24-27] that were at least
12 months long, only one [25] had at least 100 patients.
However, in that study [25], the alerting algorithm was based
on thresholds applied to the symptom score derived from a
self-reported symptom diary.
Conclusions
Given the heterogeneous nature of COPD exacerbations and
the large number of definitions in the literature, the FSM-based
approach described in this paper can help systematize the
analysis of COPD exacerbations and improve our understanding
of how symptoms worsen and of the impact of medication.
We showed that all the 3 vital signs (SpO2, respiratory rate,
pulse rate) are predictive of exacerbation events, with a
combination of these vital signs resulting in the best AUC result.
SpO2 was the most predictive vital sign, followed by respiratory
rate, and pulse rate was the least predictive. It is important to
think about the trade-off between sensitivity and specificity in
this context: false alerts will result in overmedication, but the
ability to predict exacerbations may avoid costly hospital
admissions.
None of the other classification algorithms (support vector
machines, decision trees, and k-nearest neighbor–based
classifiers) led to any significant improvement compared with
logistic regression. Additional improvements in COPD
exacerbation prediction are likely to come instead from the use
of additional physiological measures, behavioral measures, and
biomarkers (eg, temperature, heart rate variability [21], activity
[20], and sputum analysis [22]) as input to the prediction
algorithm. The other alternative is to personalize the prediction
algorithms over time and adapt the classifier to the range of
vital sign values that are typical for that particular individual.
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